1998725-11-3
1998725-11-3
Chemical Structure
JHU-083
- CAS. Nr.: 1998725-11-3
- Formula:C14H24N4O4
- Molecular Weight:312.36
IUPAC Name: ethyl (S)-2-((S)-2-amino-4-methylpentanamido)-6-diazo-5-oxohexanoate
InChIKey: YZRCHOFKIPHQBW-RYUDHWBXSA-N
SMILES: O=C(OCC)[C@H](CCC(C=[N+]=[N-])=O)NC([C@H](CC(C)C)N)=O
Biological Activity: JHU-083, a proagent of 6-diazo-5-oxo-L-norleucine (DON; HY-108357), is an orally active and selective glutaminase antagonist. JHU-083 blocks glutaminase activity in brain CD11b+ cells and experimental cerebral malaria (ECM) resulting in a net decrease of glutamate levels in the animals[1][2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
JHU-083 | 99.38% | JHU-083, a proagent of 6-diazo-5-oxo-L-norleucine (DON; HY-108357), is an orally active and selective glutaminase antagonist. JHU-083 blocks glutaminase activity in brain CD11b+ cells and experimental cerebral malaria (ECM) resulting in a net decrease of glutamate levels in the animals. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.71
HY-129905L-Leucyl-L-Leucine methyl ester hydrochloride -
Similarity Score 0.71
HY-129905AL-Leucyl-L-Leucine methyl ester hydrobromide -
Similarity Score 0.70
HY-165398L-Leucyl-L-Leucine methyl ester -
Similarity Score 0.70
HY-105723ARDuazomycin sodium (Standard) -
Similarity Score 0.69
HY-P4377H-Leu-Asp-OH -
Similarity Score 0.69
HY-P4374H-Leu-Asn-OH -
Similarity Score 0.69
HY-122323L-Leucyl-L-arginine -
Similarity Score 0.68
HY-128503TEI-2306 -
Similarity Score 0.68
HY-W008642Leu-Leu-OH -
Explore the MedChemAI to find more analogs
References
- [1]. Zhu X, et al. JHU-083 selectively blocks glutaminase activity in brain CD11b+ cells and prevents depression-associated behaviors induced by chronic social defeat stress. Neuropsychopharmacology. 2019 Mar;44(4):683-694. [Content Brief]
- [2]. Riggle BA, et al. MRI demonstrates glutamine antagonist-mediated reversal of cerebral malaria pathology in mice. Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):E12024-E12033. [Content Brief]
